This work was supported by federal funds from the National Institute of Allergy and Infectious Diseases R21 AI135537-01 (to W.B.M) and the National Center for Advancing Translational Science CTSA UL1 TR000128, Oregon Clinical and Translational Research Institute, Takeda Vaccines IISR 2016-101586 (to W.B.M), and the Sunlin and Priscilla Chou Foundation (to W.B.M.).
PLoS Neglected Tropical Diseases
Zika virus, Zika virus infection -- Epidemiology, Immunity, Immune response, Viral antigens
The recent emergence of Zika virus as an important human pathogen has raised questions about the durability and breadth of Zika virus immunity following natural infection in humans. While global epidemic patterns suggest that Zika infection elicits a protective immune response that is likely to offer long-term protection against repeat infection by other Zika viruses, only one study to date has formally examined the ability of human Zika immune sera to neutralize different Zika viruses. That study was limited because it evaluated human immune sera no more than 13 weeks after Zika virus infection and tested a relatively small number of Zika viruses. In this study, we examine twelve human Zika immune sera as far as 3 years after infection and test the sera against a total of eleven Zika virus isolates. Our results confirm the earlier study and epidemic patterns that suggest Zika virus exists in nature as a single serotype, and infection with one Zika virus can be expected to elicit protective immunity against repeat infection by any Zika virus for years to decades after the first infection.
Nix CD, Salberg J, Coulter FJ, Kareko BW, Lyski ZL, Booty BL, et al. (2020) Potency and breadth of human primary ZIKV immune sera shows that Zika viruses cluster antigenically as a single serotype. PLoS Negl Trop Dis 14(4): e0008006. https://doi.org/10.1371/journal. pntd.0008006